Linked Life Data

2791194

Source:http://linkedlifedata.com/resource/pubmed/id/2791194

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1989-11-3
pubmed:abstractText
Ifosfamide (IFS) is a new alkylating oxazaphosphorine related to cyclophosphamide. Various side effects have been reported; however, cardiotoxicity is not known to occur in humans. We report for first time acute cardiac side effects upon IFS treatment in the form of supraventricular arrhythmias and ST-T wave changes. IFS dose ranged from 6.5 g/m2 to 10 g/m2 fractionated in 3 or 5 days and infused i.v. over 4 h daily together with 2-mercaptoethane sulphonate sodium (Mesna). Arrhythmias appeared to be reversible upon discontinuation of the drug. In one patient, readministration of IFS led to arrhythmia that was refractory to treatment. Factors predisposing to the development of cardiac side effects could not be determined in this study. We suggest that patients who receive IFS treatment should be monitored for the occurrence of cardiac abnormalities. Readministration of the drug may be contraindicated in such patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
395-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Ifosfamide cardiotoxicity in humans.
pubmed:affiliation
Hellenic Anticancer Institute, St. Savas Hospital, Athens, Greece.
pubmed:publicationType
Journal Article